Conflicts of interest The authors have no conflicts of interest to declare
Medullary thyroid carcinoma history
GLP-1 Pipeline Update: November 2024 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Clinical Pharmacist, Drug Information Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Director, Pipeline Lisa Schweizer, PharmD, JD Director, Clinical Program Management Deputy Editor DISCLAIMER The drug pipeline is fluid
The results of previous trials are encouraging in terms of multiple positive effects of GLP-1 receptor agonists
When integrated into med spa weight loss programs and personalized weight loss plans, GLP-1 therapy empowers individuals to achieve their health goals while enhancing overall well-being